|
G |
Hrh1 |
histamine receptor H 1 |
multiple interactions |
ISO |
azatadine binds to and results in decreased activity of HRH1 protein |
CTD |
PMID:2864258 |
|
NCBI chr 4:147,564,963...147,649,353
Ensembl chr 4:147,645,995...147,647,455
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases export |
ISO |
ABCB1 protein results in increased export of desloratadine |
CTD |
PMID:12584158 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
ISO |
desloratadine inhibits the reaction [ABCC2 protein results in increased export of Fosinopril] |
CTD |
PMID:22095822 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Ace2 |
angiotensin converting enzyme 2 |
affects binding |
ISO |
desloratadine binds to ACE2 protein |
CTD |
PMID:33609497 |
|
NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
desloratadine results in decreased expression of BCL2 mRNA; desloratadine results in decreased expression of BCL2 protein |
CTD |
PMID:36617552 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
increases cleavage |
ISO |
desloratadine results in increased cleavage of CASP3 protein |
CTD |
PMID:36617552 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression |
ISO |
desloratadine results in decreased expression of CCNB1 protein |
CTD |
PMID:36617552 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
increases phosphorylation |
ISO |
desloratadine results in increased phosphorylation of CDK1 protein |
CTD |
PMID:36617552 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
affects chemical synthesis |
ISO |
CYP2D6 protein affects the chemical synthesis of desloratadine |
CTD |
PMID:15932952 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
F3 |
coagulation factor III, tissue factor |
increases expression |
ISO |
desloratadine results in increased expression of F3 protein |
CTD |
PMID:25569083 |
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Hpcal1 |
hippocalcin-like 1 |
affects response to substance decreases expression decreases myristoylation multiple interactions |
ISO |
HPCAL1 protein affects the susceptibility to desloratadine desloratadine results in decreased expression of HPCAL1 protein desloratadine results in decreased myristoylation of HPCAL1 protein Ammonium Chloride inhibits the reaction [desloratadine results in increased degradation of HPCAL1 protein]; desloratadine results in decreased expression of and results in increased degradation of HPCAL1 protein |
CTD |
PMID:36617552 |
|
NCBI chr 6:40,478,206...40,584,721
Ensembl chr 6:40,478,208...40,584,687
|
|
G |
Hrh1 |
histamine receptor H 1 |
affects binding |
ISO |
desloratadine binds to HRH1 protein |
CTD |
PMID:15482930 |
|
NCBI chr 4:147,564,963...147,649,353
Ensembl chr 4:147,645,995...147,647,455
|
|
G |
Il5 |
interleukin 5 |
multiple interactions |
ISO |
[montelukast co-treated with desloratadine] results in decreased expression of IL5 protein |
CTD |
PMID:15061398 |
|
NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity multiple interactions |
ISO |
desloratadine results in decreased activity of KCNH2 protein [desloratadine co-treated with Loratadine] results in decreased activity of KCNH2 protein; [Ketoconazole co-treated with desloratadine co-treated with Loratadine] results in decreased activity of KCNH2 protein; [Ketoconazole co-treated with desloratadine] results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 PMID:29143966 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Nmt1 |
N-myristoyltransferase 1 |
affects response to substance multiple interactions |
ISO |
NMT1 protein affects the susceptibility to desloratadine desloratadine binds to and results in decreased activity of NMT1 protein |
CTD |
PMID:36617552 |
|
NCBI chr10:87,988,826...88,025,405
Ensembl chr10:87,988,826...88,022,648
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
ISO |
[desloratadine results in increased susceptibility to Sorafenib] which results in increased cleavage of PARP1 protein; [Sorafenib results in increased susceptibility to desloratadine] which results in increased cleavage of PARP1 protein desloratadine results in increased cleavage of PARP1 protein |
CTD |
PMID:36617552 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
decreases phosphorylation |
ISO |
desloratadine results in decreased phosphorylation of RELA protein |
CTD |
PMID:36617552 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
desloratadine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
[Bortezomib co-treated with lonafarnib] results in decreased expression of AKT1 protein; [Bortezomib co-treated with lonafarnib] results in decreased expression of AKT1 protein modified form |
CTD |
PMID:16118318 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
lonafarnib inhibits the reaction [TNF protein results in increased expression of BCL2 protein]; lonafarnib promotes the reaction [Bortezomib results in increased cleavage of BCL2 protein modified form] |
CTD |
PMID:15090542 PMID:16118318 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2a1 |
BCL2-related protein A1 |
multiple interactions |
ISO |
lonafarnib inhibits the reaction [TNF protein results in increased expression of BCL2A1 protein] |
CTD |
PMID:15090542 |
|
NCBI chr 8:89,716,914...89,724,998
Ensembl chr 8:89,716,914...89,724,998
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions |
ISO |
lonafarnib promotes the reaction [Bortezomib results in increased cleavage of BCL2L1 protein] |
CTD |
PMID:16118318 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479 Ensembl chr 1:141,253,523...141,303,479
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
multiple interactions |
ISO |
lonafarnib inhibits the reaction [TNF protein results in increased expression of BIRC2 protein] |
CTD |
PMID:15090542 |
|
NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
multiple interactions |
ISO |
lonafarnib inhibits the reaction [TNF protein results in increased expression of BIRC3 protein] |
CTD |
PMID:15090542 |
|
NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions |
ISO |
lonafarnib inhibits the reaction [TNF protein results in increased expression of BIRC5 protein] |
CTD |
PMID:15090542 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
[lonafarnib co-treated with Bortezomib] results in increased cleavage of CASP3 protein |
CTD |
PMID:16118318 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
[lonafarnib co-treated with Bortezomib] results in increased cleavage of CASP8 protein |
CTD |
PMID:16118318 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases cleavage |
ISO |
[lonafarnib co-treated with Bortezomib] results in increased cleavage of CASP9 protein lonafarnib results in increased cleavage of CASP9 protein |
CTD |
PMID:16118318 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
lonafarnib inhibits the reaction [TNF protein results in increased expression of CCND1 protein] |
CTD |
PMID:15090542 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
multiple interactions |
ISO |
lonafarnib inhibits the reaction [TNF protein results in increased expression of CFLAR protein] |
CTD |
PMID:15090542 |
|
NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034
|
|
G |
Gsk3a |
glycogen synthase kinase 3 alpha |
multiple interactions |
ISO |
[Bortezomib co-treated with lonafarnib] results in decreased expression of GSK3A protein modified form |
CTD |
PMID:16118318 |
|
NCBI chr 1:80,815,843...80,825,732
Ensembl chr 1:80,815,850...80,825,802
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
ISO |
[Bortezomib co-treated with lonafarnib] results in decreased expression of GSK3B protein modified form |
CTD |
PMID:16118318 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
multiple interactions |
ISO |
lonafarnib inhibits the reaction [TNF protein results in increased activity of HRAS protein] |
CTD |
PMID:15090542 |
|
NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
ISO |
geraniol promotes the reaction [lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein]]; lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein] |
CTD |
PMID:21430599 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
geraniol promotes the reaction [lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein]]; lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein] |
CTD |
PMID:21430599 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Lmna |
lamin A/C |
decreases farnesylation |
ISO |
lonafarnib results in decreased farnesylation of LMNA protein |
CTD |
PMID:16996129 |
|
NCBI chr 2:173,939,751...173,960,423
Ensembl chr 2:173,939,751...173,960,423
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
lonafarnib inhibits the reaction [TNF protein results in increased expression of MMP9 protein] |
CTD |
PMID:15090542 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
lonafarnib inhibits the reaction [Hydrogen Peroxide results in increased activity of NFKB1 protein]; lonafarnib inhibits the reaction [Okadaic Acid results in increased activity of NFKB1 protein]; lonafarnib inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of NFKB1 protein]; lonafarnib inhibits the reaction [TNF protein results in increased activity of NFKB1 protein] |
CTD |
PMID:15090542 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
lonafarnib inhibits the reaction [TNF protein results in increased phosphorylation of and results in increased degradation of NFKBIA protein] |
CTD |
PMID:15090542 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
lonafarnib inhibits the reaction [TNF protein results in increased expression of PTGS2 protein] |
CTD |
PMID:15090542 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
multiple interactions |
ISO |
lonafarnib results in decreased phosphorylation of and results in decreased activity of RB1 protein |
CTD |
PMID:12673674 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
lonafarnib inhibits the reaction [Hydrogen Peroxide results in increased activity of RELA protein]; lonafarnib inhibits the reaction [Okadaic Acid results in increased activity of RELA protein]; lonafarnib inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of RELA protein]; lonafarnib inhibits the reaction [TNF protein affects the localization of RELA protein]; lonafarnib inhibits the reaction [TNF protein results in increased activity of RELA protein] |
CTD |
PMID:15090542 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rheb |
Ras homolog, mTORC1 binding |
decreases activity multiple interactions |
ISO |
lonafarnib results in decreased activity of RHEB protein [lonafarnib results in decreased activity of RHEB protein] which results in increased susceptibility to Cisplatin |
CTD |
PMID:20554106 |
|
NCBI chr 4:10,278,970...10,320,160
Ensembl chr 4:10,279,370...10,320,160
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
lonafarnib inhibits the reaction [TNF protein affects the localization of RELA protein]; lonafarnib inhibits the reaction [TNF protein results in increased activity of HRAS protein]; lonafarnib inhibits the reaction [TNF protein results in increased activity of NFKB1 protein]; lonafarnib inhibits the reaction [TNF protein results in increased activity of RELA protein]; lonafarnib inhibits the reaction [TNF protein results in increased expression of BCL2 protein]; lonafarnib inhibits the reaction [TNF protein results in increased expression of BCL2A1 protein]; lonafarnib inhibits the reaction [TNF protein results in increased expression of BIRC2 protein]; lonafarnib inhibits the reaction [TNF protein results in increased expression of BIRC3 protein]; lonafarnib inhibits the reaction [TNF protein results in increased expression of BIRC5 protein]; lonafarnib inhibits the reaction [TNF protein results in increased expression of CCND1 protein]; lonafarnib inhibits the reaction [TNF protein results in increased expression of CFLAR protein]; lonafarnib inhibits the reaction [TNF protein results in increased expression of MMP9 protein]; lonafarnib inhibits the reaction [TNF protein results in increased expression of PTGS2 protein]; lonafarnib inhibits the reaction [TNF protein results in increased expression of TRAF1 protein]; lonafarnib inhibits the reaction [TNF protein results in increased expression of XIAP protein]; lonafarnib inhibits the reaction [TNF protein results in increased phosphorylation of and results in increased degradation of NFKBIA protein] geraniol promotes the reaction [lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of TNF protein]]; lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of TNF protein] |
CTD |
PMID:15090542 PMID:21430599 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Traf1 |
TNF receptor-associated factor 1 |
multiple interactions |
ISO |
lonafarnib inhibits the reaction [TNF protein results in increased expression of TRAF1 protein] |
CTD |
PMID:15090542 |
|
NCBI chr 3:18,222,024...18,242,163
Ensembl chr 3:18,222,054...18,241,807
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
multiple interactions |
ISO |
lonafarnib inhibits the reaction [TNF protein results in increased expression of XIAP protein] |
CTD |
PMID:15090542 |
|
NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases activity multiple interactions |
ISO |
Loratadine results in decreased activity of ABCB11 protein Loratadine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] |
CTD |
PMID:23956101 PMID:24014644 PMID:28437613 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
affects response to substance increases export |
ISO |
ABCB1A protein affects the susceptibility to Loratadine ABCB1 protein results in increased export of Loratadine |
CTD |
PMID:12584158 PMID:15502009 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb1b |
ATP-binding cassette, sub-family B member 1B |
affects response to substance |
ISO |
ABCB1B protein affects the susceptibility to Loratadine |
CTD |
PMID:15502009 |
|
NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
decreases activity |
ISO |
Loratadine results in decreased activity of ABCB4 protein |
CTD |
PMID:28437613 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
decreases response to substance |
ISO |
ABCC1 protein results in decreased susceptibility to Loratadine |
CTD |
PMID:22095822 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
ISO |
Loratadine inhibits the reaction [ABCC2 protein results in increased export of Fosinopril] |
CTD |
PMID:22095822 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Ace2 |
angiotensin converting enzyme 2 |
affects binding |
ISO |
Loratadine binds to ACE2 protein |
CTD |
PMID:33609497 |
|
NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
decreases activity |
ISO |
Loratadine analog results in decreased activity of ALOX5 protein |
CTD |
PMID:15482930 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Ap1s1 |
adaptor related protein complex 1 subunit sigma 1 |
decreases expression |
ISO |
Loratadine results in decreased expression of AP1S1 mRNA |
CTD |
PMID:17567588 |
|
NCBI chr12:19,625,267...19,635,792
Ensembl chr12:19,625,332...19,756,713
|
|
G |
Ar |
androgen receptor |
increases expression |
ISO |
Loratadine results in increased expression of AR mRNA |
CTD |
PMID:16407038 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
increases expression |
ISO |
Loratadine results in increased expression of ASNS mRNA |
CTD |
PMID:15342952 PMID:17567588 |
|
NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423
|
|
G |
Casp3 |
caspase 3 |
increases cleavage multiple interactions increases activity |
ISO |
Loratadine results in increased cleavage of CASP3 protein Dasatinib promotes the reaction [Loratadine results in increased activity of CASP3 protein]; midostaurin promotes the reaction [Loratadine results in increased activity of CASP3 protein]; Palmitic Acid promotes the reaction [Loratadine results in increased activity of CASP3 protein] |
CTD |
PMID:20570632 PMID:22700542 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
increases activity multiple interactions |
ISO |
Loratadine results in increased activity of CASP7 protein Palmitic Acid promotes the reaction [Loratadine results in increased activity of CASP7 protein] |
CTD |
PMID:22700542 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp8 |
caspase 8 |
increases cleavage |
ISO |
Loratadine results in increased cleavage of CASP8 protein |
CTD |
PMID:20570632 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases cleavage |
ISO |
Loratadine results in increased cleavage of CASP9 protein |
CTD |
PMID:20570632 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
decreases activity |
ISO |
Loratadine results in decreased activity of CYP2C8 protein |
CTD |
PMID:15601807 |
|
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
affects metabolic processing |
ISO |
CYP2D6 gene polymorphism affects the metabolism of Loratadine; CYP2D6 protein affects the metabolism of Loratadine |
CTD |
PMID:15932952 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases activity |
ISO |
Loratadine analog results in decreased activity of CYP3A4 protein; Loratadine results in decreased activity of CYP3A4 protein |
CTD |
PMID:15482930 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Esr1 |
estrogen receptor 1 |
increases expression |
ISO |
Loratadine results in increased expression of ESR1 mRNA |
CTD |
PMID:16407038 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
increases expression |
ISO |
Loratadine results in increased expression of FABP1 mRNA |
CTD |
PMID:15342952 PMID:17567588 |
|
NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788
|
|
G |
Gdpd3 |
glycerophosphodiester phosphodiesterase domain containing 3 |
increases expression |
ISO |
Loratadine results in increased expression of GDPD3 mRNA |
CTD |
PMID:15342952 |
|
NCBI chr 1:181,373,505...181,383,063
Ensembl chr 1:181,366,626...181,383,063
|
|
G |
Hpn |
hepsin |
increases expression |
ISO |
Loratadine results in increased expression of HPN mRNA |
CTD |
PMID:15342952 |
|
NCBI chr 1:86,337,085...86,352,785
Ensembl chr 1:86,337,087...86,352,811
|
|
G |
Hrh1 |
histamine receptor H 1 |
affects binding |
ISO |
Loratadine analog binds to HRH1 protein; Loratadine binds to HRH1 protein |
CTD |
PMID:15482930 |
|
NCBI chr 4:147,564,963...147,649,353
Ensembl chr 4:147,645,995...147,647,455
|
|
G |
Inhbe |
inhibin subunit beta E |
increases expression |
ISO |
Loratadine results in increased expression of INHBE mRNA |
CTD |
PMID:15342952 PMID:17567588 |
|
NCBI chr 7:63,176,221...63,179,209
Ensembl chr 7:63,176,219...63,179,172
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity affects activity multiple interactions |
ISO |
Loratadine results in decreased activity of KCNH2 protein Loratadine affects the activity of KCNH2 protein [desloratadine co-treated with Loratadine] results in decreased activity of KCNH2 protein; [Ketoconazole co-treated with desloratadine co-treated with Loratadine] results in decreased activity of KCNH2 protein; [Ketoconazole co-treated with Loratadine] results in decreased activity of KCNH2 protein; Loratadine binds to and results in decreased activity of KCNH2 protein; Loratadine inhibits the reaction [KCNH2 protein results in increased transport of Thallium] |
CTD |
PMID:9658196 PMID:10604956 PMID:11705456 PMID:16278312 PMID:21158687 PMID:29143966 More...
|
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Lss |
lanosterol synthase |
increases expression |
ISO |
Loratadine results in increased expression of LSS mRNA |
CTD |
PMID:15342952 |
|
NCBI chr20:12,091,138...12,118,858
Ensembl chr20:12,092,774...12,118,762
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
increases expression |
ISO |
Loratadine results in increased expression of NR0B2 mRNA |
CTD |
PMID:15342952 |
|
NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609
|
|
G |
Nupr1 |
nuclear protein 1, transcriptional regulator |
increases expression |
ISO |
Loratadine results in increased expression of NUPR1 mRNA |
CTD |
PMID:15342952 PMID:17567588 |
|
NCBI chr 1:181,213,292...181,215,327
Ensembl chr 1:181,213,368...181,215,281
|
|
G |
Rps6 |
ribosomal protein S6 |
decreases expression |
ISO |
Loratadine results in decreased expression of RPS6 protein modified form |
CTD |
PMID:20570632 |
|
NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602 Ensembl chr 5:101,371,136...101,374,602
|
|
G |
Serpina3n |
serpin family A member 3N |
increases expression |
ISO |
Loratadine results in increased expression of SERPINA3 mRNA |
CTD |
PMID:15342952 |
|
NCBI chr 6:123,323,623...123,331,181
Ensembl chr 6:123,323,629...123,332,433
|
|
G |
Slc2a3 |
solute carrier family 2 member 3 |
decreases expression |
ISO |
Loratadine results in decreased expression of SLC2A3 mRNA |
CTD |
PMID:15342952 PMID:17567588 |
|
NCBI chr 4:155,960,944...156,026,000
Ensembl chr 4:155,960,946...156,025,472
|
|
G |
Slpi |
secretory leukocyte peptidase inhibitor |
increases expression |
ISO |
Loratadine results in increased expression of SLPI mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:153,082,208...153,084,457
Ensembl chr 3:153,082,369...153,084,453
|
|
G |
Tagln |
transgelin |
decreases expression |
ISO |
Loratadine results in decreased expression of TAGLN mRNA |
CTD |
PMID:15342952 PMID:17567588 |
|
NCBI chr 8:46,224,939...46,230,413
Ensembl chr 8:46,222,472...46,230,668
|
|